ABCMdb

ABCA4 p.Gly2146Asp

ClinVar:	c.6437G>A , p.Gly2146Asp ? , not provided
Predicted by SNAP2:	A: N (61%), C: D (53%), D: D (95%), E: N (53%), F: D (71%), H: N (57%), I: D (66%), K: N (53%), L: D (66%), M: D (66%), N: N (66%), P: D (53%), Q: N (61%), R: N (53%), S: N (72%), T: N (61%), V: D (59%), W: D (85%), Y: D (71%),
Predicted by PROVEAN:	A: D, C: D, D: D, E: D, F: D, H: D, I: D, K: D, L: D, M: D, N: D, P: D, Q: D, R: D, S: D, T: D, V: D, W: D, Y: D,

[switch to compact view]
Comments [show]

None has been submitted yet.

Publications
[hide] Functional analysis of genetic mutations in nucleo... Biochemistry. 2003 Sep 16;42(36):10683-96. Biswas-Fiss EE
Functional analysis of genetic mutations in nucleotide binding domain 2 of the human retina specific ABC transporter.
Biochemistry. 2003 Sep 16;42(36):10683-96., [PMID:12962493]

Abstract [show]
The rod outer segment (ROS) ABC transporter (ABCR) plays an important role in the outer segment of retinal rod cells, where it functions as a transporter of all-trans retinal, most probably as the complex lipid, retinylidene-phosphatidyl-ethanolamine. We report here a quantitative analysis of the structural and functional effects of genetic mutations, associated with several macular degenerations, in the second nucleotide-binding domain of ABCR (NBD2). We have analyzed the ATP binding, kinetics of ATP hydrolysis, and structural changes. The results of these multifaceted analyses were correlated with the disease severity and prognosis. Results presented here demonstrated that, in wild type NBD2, distinct conformational changes accompany nucleotide (ATP and ADP) binding. Upon ATP binding, NBD2 protein changed to a relaxed conformation where tryptophans became more solvent-exposed, while ADP binding reverses this process and leads back to a taut conformation that is also observed with the unbound protein. This sequence of conformational change appears to be important in the energetics of the ATP hydrolysis and may have important structural consequences in the ability of the NBD2 domain to act as a regulator of the nucleotide-binding domain 1. Some of the mutant proteins displayed strikingly different patterns of conformational changes upon nucleotide binding that pointed to unique structural consequences of these genetic mutations. The ABCR dysfunctions, associated with various retinopathies, are multifaceted in nature and include alterations in protein structure as well as the attenuation of ATPase activity and nucleotide binding.

Comments [show]

None has been submitted yet.

Sentences [show]
No. Sentence Comment
73 The NBD2 expression vector pET29aNBD2 was used as template, 12 cycles of PCR, and each cycle was 30 s at 95 °C, 30 s at 50 °C, and 15 min at 68°C using complimentary oligonucleotides to produce the mutations L1971R, R2038W, G2146D, K2175A, and D2177N. Login to comment
74 The primers used for mutagenesis were as follows: L1971R, CGC CCT GGA GAG TGC TTT GGC CTC CGG GGA GTG AAT GGT GCC GGC AAA AC; R2038W, CTT TAC CTT TAT GCC AGG CTT CGA GGT GTA CCA GC, G2146D, CTG GCC ATC ATG GTA AAG GAC GCC TTT CGA TGT AT; D2177N, ATC AAA TCC CCG AAG GAC AAC CTG CTT CCT GAC CTG AAC; K2175A, CA ATG AAG ATC AAA TCC CCG GCG GAC GAC CTG CTT CCT GA. All of the mutations were disease-associated with the exception of K2175A. Login to comment
103 The locations of the disease associated mutations investigated in this study; L1971R, R2038W, G2146D, L2027F, and D2177N are indicated. Login to comment
144 Here, we have used site-specific mutagenesis to create disease-related genetic mutations: L1971R, D2177N, L2027F, R2038W, and G2146D as well as a synthetic mutation, K2175A. Login to comment
153 Lane 1: protein molecular weight standards; lane 2, wild-type NBD2; lane 3, L2027F mutant; lane 4, L1971R mutant; lane 5, D2177N; lane 6, G2146D; lane 7, R2038W mutant; lane 8, K2175A. Login to comment
176 In the mutation G2146D, the specific ATPase activity was reduced to approximately 70% of that observed with the wild type, and the rate of hydrolysis (65 nm/min/mg) was 56% of the wild-type NBD2. Login to comment
179 The G2146D and R2038W mutations are associated with cone-rod dystrophy and Stargardt disease, respectively. These two degenerative syndromes are more severe than FFM or AMD, with respect to age of onset and time frame of disease progression. Login to comment
227 The binding constants for both G2146D and R2038W decreased as compared to the wild-type control (Figure 6C,D). Login to comment
228 The affinity for ATP was quite similar for both mutants; the G2146D Kd was 1.33 × 10-6 M while that of R2038W was 1.32 × 10-6 M (Table 1). Login to comment
253 The curves represent a least squares nonlinear regression curve fit of the data representing the (A) L1971R mutant, (B) D2177N mutant, (C) G2146D mutant, (D) R2038W mutant, and (E) K2175A mutant. Login to comment
267 Stern Volmer plots of the (A) wild-type NBD2, (B) L1971R mutant, (C) L2027F mutant, (D) D2177N mutant, (E) R2038W mutant, (F) G2146D mutant, and (F) K2175A mutant. Login to comment
282 The R2038W and G2146D quenching profiles (Figure 7E,F and Table 1) had notable differences when compared to that of the wild-type protein. Login to comment
284 In the case of G2146D, the maximum percent quenching observed was ATP bound, 23%, ADP 13%, nucleotide-free 15%. Login to comment
290 Clinically, the alteration of pattern of conformational change correlated well with the disease severity, since the mutations G2146D and R2038W are associated with STDG1 and CRD, which have an earlier age of onset and/or more rapid progression of disease. Login to comment
303 The mutation L1971R has been identified with individuals suffering from the milder form of macular degeneration, Fundus Flavimaculatus, while G2146D and R2038W are associated with STGD1 and CRD, both of which are more severe forms of degeneration. Login to comment
305 In this study, the mutations R2038W, L1971R and G2146D led to comparable (~50%) decreases in ATP hydrolysis relative to the wild-type control. Login to comment
353 The mutants R2038W and G2146D had comparable differences in nucleotide hydrolysis and thermodynamics of ATP binding. Login to comment
354 The G2146D had more closed conformations in free and nucleotide bound states; the extent of quenching for NBD2‚ATP was only 23%; the nucleotide-free and ADP-bound forms were nearly equivalent, 12% and 15%, respectively, reflecting a more closed conformation than that of wild type. Login to comment

[hide] Mutations in ABCR (ABCA4) in patients with Stargar... Invest Ophthalmol Vis Sci. 2001 Sep;42(10):2229-36. Briggs CE, Rucinski D, Rosenfeld PJ, Hirose T, Berson EL, Dryja TP
Mutations in ABCR (ABCA4) in patients with Stargardt macular degeneration or cone-rod degeneration.
Invest Ophthalmol Vis Sci. 2001 Sep;42(10):2229-36., [PMID:11527935]

Abstract [show]
PURPOSE: To determine the spectrum of ABCR mutations associated with Stargardt macular degeneration and cone-rod degeneration (CRD). METHODS: One hundred eighteen unrelated patients with recessive Stargardt macular degeneration and eight with recessive CRD were screened for mutations in ABCR (ABCA4) by single-strand conformation polymorphism analysis. Variants were characterized by direct genomic sequencing. Segregation analysis was performed on the families of 20 patients in whom at least two or more likely pathogenic sequence changes were identified. RESULTS: The authors found 77 sequence changes likely to be pathogenic: 21 null mutations (15 novel), 55 missense changes (26 novel), and one deletion of a consensus glycosylation site (also novel). Fifty-two patients with Stargardt macular degeneration (44% of those screened) and five with CRD each had two of these sequence changes or were homozygous for one of them. Segregation analyses in the families of 19 of these patients were informative and revealed that the index cases and all available affected siblings were compound heterozygotes or homozygotes. The authors found one instance of an apparently de novo mutation, Ile824Thr, in a patient. Thirty-seven (31%) of the 118 patients with Stargardt disease and one with CRD had only one likely pathogenic sequence change. Twenty-nine patients with Stargardt disease (25%) and two with CRD had no identified sequence changes. CONCLUSIONS: This report of 42 novel mutations brings the growing number of identified likely pathogenic sequence changes in ABCR to approximately 250.

Comments [show]

None has been submitted yet.

Sentences [show]
No. Sentence Comment
89 ABCR Sequence Changes Found in 118 Patients with Stargardt and 8 with CRD Patient ID Mutations (Amino Acid Based) Sequence Change (Nucleotide Based) Het/Hom Other Sequence Changes 21 Null Mutations 071-004 Met1Val ATG 3 GTC Het None 035-002* Ser84(insCAAA)30 251ins4 Het IVS36 ϩ 1G 3 A 034-039 Ser84(insCAAA)30 251ins4 Het Gly1961Glu 032-018 Arg152Ter23 CGA 3 TGA Het Arg2107Cys 032-005 Ala222(del13bp) 666del13 [AAAGACGGTGCGC] Het None 032-039 Ala222(del13bp) 666del13 [AAAGACGGTGCGC] Het None 032-060 [Ser278(delT); Arg1300Gln] [832delT; CGA 3 CAA] Het Pro1486Leu 032-066* Lys356Ter AAG 3 TAG Het Gln1513(insC) 032-072 - IVS13 ϩ 2T 3 C Het Val77Glu 032-073 Arg681Ter21 CGA 3 TGA Het Leu1388Pro 034-016 Ser1071(insGT)31 3212insGT Het None 032-065 Ser1071(insGT)31 3212insGT Het None 035-003 Ile1114(delC)5 3340delC Het Pro1380Leu 007-014* - IVS26 ϩ 1G 3 A Het Asn1345(insCA) 007-014* Asn1345(insCA) 4034insCA Het IVS26 ϩ 1G 3 A 032-066* Gln1513(insC) 4538insC Het Lys356Ter 032-010 Gln1513(insC) 4538insC Het None 032-024 Pro1570(delC)16 4710delC Het Gly1961Glu 032-016 Thr1721 (delAC) delete AC @ nt 5161 Het Thr1525Met 035-002* - IVS36 ϩ 1G 3 A23 Het Ser84(insCAAA) 034-031 Leu1741(del11) 5194del11 [GTGGTGGGCAT] Het Gly1961Glu 032-051 Trp1772Ter TGG 3 TGA Het None 032-022 - IVS41-2delA Het Gly1961Glu 032-081* Val1973(delG) 5917delG Hom None 034-017 Gly2100(delG) 6300delG Het Gly1961Glu 55 Missense and One In-Frame Deletion 032-020 Cys54Tyr15 TGC 3 TAC Het Gly863Ala 035-012 Cys54Tyr15 TGC 3 TAC Het Arg1108Cys 071-007 Cys54Tyr15 TGC 3 TAC Het Val935Ala 071-003 Asn58Lys AAC 3 AAG Het Leu1201Arg 032-069 Ala60Val15 GCG 3 GTG Het None 032-028 Gly65Glu16 GGA 3 GAA Het None 032-072 Val77Glu GTG 3 CAG Het IVS13 ϩ 2T 3 C 034-013 Gln190His CAG 3 CAC Het Gly1961Glu 032-076 Leu244Pro CTG 3 CCG Hom None 032-012 Pro309Arg CCA 3 CGA Het Arg1300Gln 032-054 Phe525Cys TTT 3 TGT Het Ile1846Thr 032-046 Arg537Cys CGT 3 TGT Het Val989Ala 034-038 Arg537Cys CGT 3 TGT Het Gly863Ala 032-095 Leu541Pro18 CTA 3 CCA Het None 034-022 Leu541Pro18 CTA 3 CCA Het Leu2027Phe 035-001 Leu541Pro18 CTA 3 CCA Het None 032-009 Leu541Pro18 CTA 3 CCA Het None 032-023 [Leu541Pro18 ; Ala1038Val27 ] [CTA 3 CCA; GCC 3 GTC] Het Gly863Ala 034-035 [Leu541Pro18 ; Ala1038Val27 ] [CTA 3 CCA; GCC 3 GTC] Het Gly863Ala 032-011 Ala549Pro GCC 3 CCC Het Gly1961Glu 032-044 Gly550Arg GGA 3 AGA Het None 032-085 Arg602Gln CGG 3 CAG Het Val643Met 032-090 Gly607Arg GGG 3 AGG Het Leu2027Phe 032-085 Val643Met GTG 3 ATG Het Arg602Gln 032-042 Val767Asp30 GTC 3 GAG Het Pro1486Leu 071-006 Val767Asp30 GTC 3 GAG Het Ile1562Thr 032-014 Leu797Pro CTG 3 CCG Het Pro1486Leu 032-038 Trp821Arg18 TGG 3 AGG Het None 034-045 Ile824Thr ATC 3 ACC Het Gly1961Glu 032-056 Gly863Ala5 GGA 3 GCA Het None 032-091 Gly863Ala5 GGA 3 GCA Het None 032-020 Gly863Ala5 GGA 3 GCA Het Cys54Tyr 032-023 Gly863Ala5 GGA 3 GCA Het [Leu541Pro; Ala1038Val] 034-011 Gly863Ala5 GGA 3 GCA Het Cys1488Arg 034-015 Gly863Ala5 GGA 3 GCA Het Thr1525Met 034-035 Gly863Ala5 GGA 3 GCA Het [Leu541Pro; Ala1038Val] 034-036 Gly863Ala5 GGA 3 GCA Het Cys2150Arg 034-038 Gly863Ala5 GGA 3 GCA Het Arg537Cys 071-007 Val935Ala GTA 3 GCA Het Cys54Tyr 032-043 Arg943Trp CGG 3 TGG Het Arg1108Leu 032-046 Val989Ala GTT 3 GCT Het Arg537Cys 071-005 Arg1108Cys18 CGC 3 TGC Het None Patient ID Mutations (Amino Acid Based) Sequence Change (Nucleotide Based) Het/Hom Other Sequence Changes 035-012 Arg1108Cys18 CGC 3 TGC Het Cys54Tyr 032-043 Arg1108Leu5 CGC 3 CTC Het Arg943Trp 032-097 Glu1122Lys18 GAG 3 AAG Het None 035-019 Glu1122Lys18 GAG 3 AAG Het None 071-003 Leu1201Arg15 CTG 3 CGG Het Asn58Lys 032-012 Arg1300Gln CGA 3 CAA Het Pro309Arg 032-068 Arg1300Gln CGA 3 CAA Het None 032-013 Pro1380Leu15 CCG 3 CTG Het Gly1961Glu 032-015 Pro1380Leu15 CCG 3 CTG Het Gly1961Glu 032-027 Pro1380Leu15 CCG 3 CTG Het Gly1961Glu 071-001 Pro1380Leu15 CCG 3 CTG Hom None 034-020 Pro1380Leu15 CCG 3 CTG Het Leu2027Phe 034-028 Pro1380Leu15 CCG 3 CTG Het Gly1961Glu 034-044 Pro1380Leu15 CCG 3 CTG Het Leu2027Phe 034-048 Pro1380Leu15 CCG 3 CTG Het Gly1961Glu 035-003 Pro1380Leu15 CCG 3 CTG Het Ile1114(delC) 032-073 Leu1388Pro CTG 3 CCG Het Arg681Ter 034-040 Trp1408Arg15 TGG 3 CGG Het Arg1640Trp 035-013 Trp1408Arg15 TGG 3 CGG Het Arg1640Trp 032-060 Pro1486Leu20 CCA 3 CTA Het [Ser278(delT); Arg1300Gln] 032-014 Pro1486Leu20 CCA 3 CTA Het Leu797Pro 032-025 Pro1486Leu20 CCA 3 CTA Het Asp1531Asn 032-042 Pro1486Leu20 CCA 3 CTA Het Val767Asp 034-011 Cys1488Arg15 TGC 3 CGC Het Gly863Ala 032-034 Cys1490Tyr15 TGC 3 TAC Het Ile1846Thr 032-084 Thr1525Met15 ACG 3 ATG Het Arg2139Trp 032-016 Thr1525Met15 ACG 3 ATG Het Thr1721(delAC) 032-021 Thr1525Met15 ACG 3 ATG Het None 032-041 Thr1525Met15 ACG 3 ATG Het None 034-015 Thr1525Met15 ACG 3 ATG Het Gly863Ala 032-049 Asp1531Asn15 GAC 3 AAC Het Gly1961Glu 034-019 Asp1531Asn15 GAC 3 AAC Het None 032-025 Asp1531Asn15 GAC 3 AAC Het Pro1846Leu 071-006 Ile1562Thr27 ATT 3 ACT Het Val767Asp 034-040 Arg1640Trp18 CGG 3 TGG Het Trp1408Arg 035-013 Arg1640Trp18 CGG 3 TGG Het Trp1408Arg 032-030* Arg1640Gln CGG 3 CAG Hom None 032-019 Pro1776Leu CCC 3 CTC Het Gly1961Glu 032-034 Ile1846Thr21 ATT 3 ACT Het Cys1490Tyr 032-054 Ile1846Thr21 ATT 3 ACT Het Phe525Cys 032-011 Gly1961Glu27 GGA 3 GAA Het Ala549Pro 032-013 Gly1961Glu27 GGA 3 GAA Het Pro1380Leu 032-015 Gly1961Glu27 GGA 3 GAA Het Pro1380Leu 032-019 Gly1961Glu27 GGA 3 GAA Het Pro1776Leu 032-022 Gly1961Glu27 GGA 3 GAA Het IVS41-2delA 032-024 Gly1961Glu27 GGA 3 GAA Het Pro1570(delC) 032-027 Gly1961Glu27 GGA 3 GAA Het Pro1380Leu 032-040 Gly1961Glu27 GGA 3 GAA Het None 032-049 Gly1961Glu27 GGA 3 GAA Het Asp1531Asn 034-013 Gly1961Glu27 GGA 3 GAA Het Gln190His 034-017 Gly1961Glu27 GGA 3 GAA Het Gly2100(delG) 034-021 Gly1961Glu27 GGA 3 GAA Het None 034-025 Gly1961Glu27 GGA 3 GAA Het None 034-028 Gly1961Glu27 GGA 3 GAA Het Pro1380Leu 034-031 Gly1961Glu27 GGA 3 GAA Het Leu1741(del11) 034-033 Gly1961Glu27 GGA 3 GAA Het None 034-039 Gly1961Glu27 GGA 3 GAA Het Ser84(insCAAA) 032-050 Gly1961Glu27 GGA 3 GAA Het None 034-045 Gly1961Glu27 GGA 3 GAA Het Ile824Thr 034-048 Gly1961Glu27 GGA 3 GAA Het Pro1380Leu 032-003 Gly1977Ser15 GGC 3 AGC Het Leu2027Phe 032-003 Leu2027Phe5 CTC 3 TTC Het Gly1977Ser 032-090 Leu2027Phe5 CTC 3 TTC Het Gly607Arg 034-006 Leu2027Phe5 CTC 3 TTC Het None 034-020 Leu2027Phe5 CTC 3 TTC Het Pro1380Leu 034-022 Leu2027Phe5 CTC 3 TTC Het Leu541Pro 034-044 Leu2027Phe5 CTC 3 TTC Het Pro1380Leu 035-011 Leu2027Phe5 CTC 3 TTC Het None 032-063 Arg2030Gln15 CGA 3 CAA Het None 032-093 Arg2030Gln15 CGA 3 CAA Het None 2232 Briggs et al. IOVS, September 2001, Vol. 42, No. Login to comment
91 ABCR Sequence Changes Found in 118 Patients with Stargardt and 8 with CRD Patient ID Mutations (Amino Acid Based) Sequence Change (Nucleotide Based) Het/Hom Other Sequence Changes 071-002 Leu2035Pro CTT 3 CCT Het None 032-064 Val2050Leu5 GTT 3 CTT Het None 032-061 Arg2107His18 CGC 3 CAC Het None 032-018 Arg2107Cys CGC 3 TGC Het Arg152Ter 032-084 Arg2139Trp CGG 3 TGG Het Thr1525Met 007-009* Gly2146Asp GGC 3 GAC Het None 032-045 Cys2150Tyr16 TGT 3 TGC Hom None 034-036 Cys2150Arg TGT 3 CGT Het Gly863Ala 034-026 Deletion Lys13-Trp15 38del9 [AGAACTGGA] Het None 034-037 Deletion Lys13-Trp15 38del9 [AGAACTGGA] Het None Polymorphisms and Rare Variants Sequence Change Alleles Among 126 Patients (n) Alleles Among Controls (n) P† 6 Nonpathogenic Missense Changes Arg212His23 CGC 3 CAC 8 10/(188) 0.3 His423Arg23 CAC 3 CGC 34 14/(178) 0.09 Arg943Gln27 CGG 3 CAG 15 9/(190) 0.7 Ala1637Thr GCC 3 ACC 1 - Not determined Asn1868Ile21 AAT 3 ATT 41 50/(170) 0.002 Pro1948Leu21 CCA 3 CTA 10 4/(190) 0.4 35 Intron and Isocoding Changes Pro47Pro CCG 3 CCA - IVS3 - 71delA - IVS3 ϩ 20C 3 T - IVS3 ϩ 26A 3 G - IVS3 ϩ 92A 3 G - IVS6 - 32T 3 C23 Thr311Thr ACC 3 ACT - IVS9 - 14C 3 T - IVS10 ϩ 6insC - IVS10 ϩ 11delG Ala626Ala GCG 3 GCA Leu988Leu CTC 3 CTT - IVS22 - 34A 3 G Pro1401Pro21 CCC 3 CCA - IVS32 - 38C 3 T23 - IVS32 - 15C 3 T - IVS33 - 16delGT23 - IVS35 - 32G 3 A - IVS38 - 50delA - IVS38 - 10T 3 C - IVS39 ϩ 6del12 [TGGTAGCCGAGG]: ins11 [CGGTCGAGGGC] - IVS40 - 25A 3 C Leu1894Leu21 CTG 3 CTC - IVS41 - 10A 3 G Leu1938Leu23 TTA 3 TTG Pro1948Pro21 CCA 3 CCG Ile2023Ile ATC 3 ATT Ile2083Ile27 ATC 3 ATT - IVS45 ϩ 7G 3 A32 Asp2095Asp21 GAT 3 GAC - IVS48 ϩ 21 C 3 T - IVS48 - 3 T 3 C - IVS49 - 85 C 3 T - IVS49 ϩ 28 G 3 C Val2244Val GTG 3 GTA References for previously reported changes are indicated in superscript in the first column (for exon sequence changes) or the second column (for intron sequence changes). Login to comment
158 A fifth patient with CRD (032-030) was homozygous for the missense change Arg1640Gln and a sixth patient (007-009) had the missense change Gly2146Asp and no other sequence changes that we were able to detect. Login to comment
155 A fifth patient with CRD (032-030) was homozygous for the missense change Arg1640Gln and a sixth patient (007-009) had the missense change Gly2146Asp and no other sequence changes that we were able to detect. Login to comment